Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Bronowicki, V. Venard, Christine Botté, N. Monhoven, I. Gastin, L. Choné, H. Hudziak, B. Rhin, Christophe Delanoë, A. Lefaou, M. Bigard, P. Gaucher (1997)
Patient-to-patient transmission of hepatitis C virus during colonoscopy.The New England journal of medicine, 337 4
(1994)
HCV amplicor-Lipa combined procedure. Validation and bene®t
R. Purcell (1994)
Hepatitis viruses: changing patterns of human disease.Proceedings of the National Academy of Sciences of the United States of America, 91 7
U. Comandini, G. Tossini, M. Longo, F. Ferri, G. Cuzzi, P. Noto, M. Zaccarelli, G. Visco (1998)
Sporadic hepatitis C virus infection: a case-control study of transmission routes in a selected hospital sample of the general population in Italy.Scandinavian journal of infectious diseases, 30 1
M. Chiaramonte, T. Stroffolini, U. Lorenzoni, F. Minniti, S. Conti, A. Floreani, Efrem Ntakirutimana, Alfredo Vian, T. Ngatchu, R. Naccarato (1996)
Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy.Journal of hepatology, 24 2
El‐Serag El‐Serag, Mason Mason (1999)
Rising incidence of hepatocellular carcinoma in the United StatesN Engl J Med, 340
J. McHutchison, S. Gordon, E. Schiff, M. Shiffman, William Lee, V. Rustgi, Z. Goodman, M. Ling, S. Cort, J. Albrecht (1998)
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.The New England journal of medicine, 339 21
Mele, Tosti, Marzolini, Moiraghi, Ragni, Gallo, Balocchini, Santonastasi, Stroffolini (2000)
Prevention of hepatitis C in Italy: lessons from surveillance of type‐specific acute viral hepatitisJournal of Viral Hepatitis, 7
P. Simmonds, A. Alberti, H. Alter, F. Bonino, D. Bradley, C. Bréchot, J. Brouwer, Shiu-Wan Chan, K. Chayama, Ding‐Shinn Chen, Q. Choo, M. Colombo, H. Cuypers, T. Date, G. Dusheiko, J. Esteban, O. Fay, S. Hadziyannis, Jang Han, A. Hatzakis, E. Holmes, H. Hotta, M. Houghton, B. Irvine, M. Kohara, J. Kolberg, G. Kuo, J. Lau, P. Lelie, G. Maertens, F. Mcomish, T. Miyamura, M. Mizokami, A. Nomoto, A. Prince, H. Reesink, C. Rice, M. Roggendorf, S. Schalm, T. Shikata, K. Shimotohno, L. Stuyver, C. Trepo, A. Weiner, P. Yap, M. Urdea (1994)
A proposed system for the nomenclature of hepatitis C viral genotypesHepatology, 19
B. Pereira, A. Levey (1997)
Hepatitis C virus infection in dialysis and renal transplantation.Kidney international, 51 4
G. Dusheiko, H. Schmilovitz-Weiss, David Brown, F. Mcomish, P. Yap, S. Sherlock, N. Mcintyre, P. Simmonds (1994)
Hepatitis C virus genotypes: An investigation of type‐specific differences in geographic origin and diseaseHepatology, 19
P. Halfon, M. Bourliere, G. Halimi, G. Cartouzour, V. Gérolami, J. Raabe, C. Renoux, H. Riflet, D. Ouzan (1998)
Molecular epidemiology of the transmission of hepatitis C virus between vireamic regular spouses
F. Dubois, J. Desenclos, N. Mariotte, A. Goudeau (1997)
Hepatitis C in a French population‐based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factorsHepatology, 25
Y. KARENK., Young, R. Resnick, T. Myers (1993)
Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assayJournal of Clinical Microbiology, 31
M. Martinot‐Peignoux, Françoise Roudot-Thoraval, I. Mendel, Joliette Coste, Jacques Izopet, G. Duverlie, Christopher Payan, J. Pawlotsky, C. Defer, Marc Bogard, V. Gérolami, P. Halfon, Y. Buisson, B. Fouqueray, P. Loiseau, Jérôme Lamoril, J. Lefrère, P. Marcellin (1999)
Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapyJournal of Viral Hepatitis, 6
G. Pugliese, M. Favero (1999)
Rising Incidence of Hepatocellular Carcinoma in the United StatesInfection Control & Hospital Epidemiology, 20
Y. Ko, M. Ho, T. Chiang, Shun-Jen Chang, Po-ya Chang (1992)
Tattooing as a risk of hepatitis C virus infectionJournal of Medical Virology, 38
J. Gournay, P. Marcellin, M. Martinot-Peignoux, F. Gabriel, S. Erlinger, J. Benhamou, C. Degott, F. Courtois, M. Branger, A. Wild (1995)
Hepatitis C virus genotypes in French blood donorsJournal of Medical Virology, 45
T. Poynard, P. Marcellin, S. Lee, C. Niederau, G. Minuk, G. Idéo, V. Bain, J. Heathcote, S. Zeuzem, C. Trépo, J. Albrecht (1998)
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)Lancet, 352 9138
S. Pol, V. Thiers, J. Nousbaum, C. Legendre, P. Berthelot, H. Kreis, C. Bréchot, C. Bréchot (1995)
The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients.Gastroenterology, 108 2
M. Mondelli, E. Silini (1999)
Clinical significance of hepatitis C virus genotypes.Journal of hepatology, 31 Suppl 1
(1994)
The European Liver Transplant Registry Report. Villejuif: Ho Ãpital Paul Brousse
O. Reichard, G. Norkrans, A. Frydén, J. Braconier, A. Sönnerborg, O. Weiland (1998)
Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group.Lancet, 351 9096
S. Deuffic, T. Poynard, A. Valleron (1999)
Correlation between hepatitis C virus prevalence and hepatocellular carcinoma mortality in EuropeJournal of Viral Hepatitis, 6
H. Feucht, M. Schröter, B. Zöllner, S. Polywka, Hartmut Nolte, R. Laufs (1997)
The influence of age on the prevalence of hepatitis C virus subtypes 1a and 1b.The Journal of infectious diseases, 175 3
Forns Forns, Bukh Bukh (1999)
The molecular biology of hepatitis C virusClinics Liver Dis, 3
J. Westin, M. Lindh, L. Lagging, G. Norkrans, R. Wejstål (1999)
Chronic hepatitis C in Sweden: genotype distribution over time in different epidemiological settings.Scandinavian journal of infectious diseases, 31 4
R. Knodell, K. Ishak, W. Black, Thomas Chen, R. Craig, N. Kaplowitz, T. Kiernan, J. Wollman (1981)
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitisHepatology, 1
Weekly Epidemiol Record, 72
P. Bedossa, T. Poynard (1996)
An algorithm for the grading of activity in chronic hepatitis CHepatology, 24
L. Benvegnu', P. Pontisso, D. Cavalletto, F. Noventa, L. Chemello, A. Alberti (1997)
Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus‐related cirrhosisHepatology, 25
Pereira Pereira, Levey Levey (1997)
Hepatitis C virus in dialysis units and renal transplantationKidney Int, 51
P. Halfon, H. Khiri, V. Gérolami, M. Bourliere, J. Feryn, P. Reynier, A. Gauthier, G. Cartouzou (1996)
Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA.Journal of hepatology, 25 3
J. Bukh, Roger Miller, R. Purcell (1995)
Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and GenotypesSeminars in Liver Disease, 15
G. Davis, R. Esteban-Mur, V. Rustgi, J. Hoefs, S. Gordon, C. Trépo, M. Shiffman, S. Zeuzem, A. Craxì, M. Ling, J. Albrecht (1998)
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.The New England journal of medicine, 339 21
O. Reichard, G. Norkrans, A. Frydén, J. Braconier, A. Sönnerborg, O. Weiland (1998)
Randomised, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis CThe Lancet, 351
G. Davis, J. Lau (1997)
Factors predictive of a beneficial response to therapy of hepatitis CHepatology, 26
Davis Davis, Esteban‐Mur Esteban‐Mur, Rustgi Rustgi (1998)
For the Hepatitis Interventional Therapy Group. Interferon alpha 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis CN Engl J Med, 339
Bedossa Bedossa, Poynard Poynard (1996)
The METAVIR cooperative study group. An algorithm for the grading of activity in chronic hepatitis CHepatalogy, 24
P. Simmonds (1995)
Variability of hepatitis C virusHepatology (Baltimore, Md.), 21
D. Lucidarme, P. Foutrein, C. Creusy, G. Forzy, M. Foutrein-Comes, A. Muyssen, D. Bailly, P. Parquet, B. Filoche (1994)
[Prevalence of hepatitis C, B and D markers and histopathological aspects in a group of intravenous drug addicts].Gastroenterologie clinique et biologique, 18 11
L. Roffi, A. Ricci, C. Ogliari, A. Scalori, E. Minola, G. Colloredo, C. Donada, R. Ceriani, Gianni Rinaldi, B. Paris, G. Fornaciari, Rino Morales, P. Poggio, A. Sangiovanni, Marco Buonocore, V. Bellia, P. Riboli, M. Nava, F. Panizzuti, A. Piperno, M. Pozzi, P. Pioltelli, G. Mancia (1998)
HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients.Journal of hepatology, 29 5
H. Rosen, S. Chou, A. Sasaki, D. Gretch (1999)
Molecular epidemiology of hepatitis C infection in U.S. veteran liver transplant recipients: evidence for decreasing relative prevalence of genotype 1BAmerican Journal of Gastroenterology, 94
J. Nousbaum, S. Pol, B. Nalpas, P. Landais, P. Berthelot, C. Bréchot (1995)
Hepatitis C Virus Type 1b (II) Infection in France and ItalyAnnals of Internal Medicine, 122
McHutchison McHutchison, Gordon Gordon, Schiff Schiff (1998)
Interferon alpha 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis CN Engl J Med, 339
D. Hosmer, S. Lemeshow (1991)
Applied Logistic Regression
K. Fukuizumi, M. Sata, Hiroshi Suzuki, H. Nakano, Kyuchi Tanikawa (1997)
Hepatitis C virus seroconversion rate in a hyperendemic area of HCV in Japan: a prospective study.Scandinavian journal of infectious diseases, 29 4
T. Poynard, J. McHutchison, Z. Goodman, M. Ling, J. Albrecht (2000)
Is an “à la carte” combination interferon alfa‐2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C?Hepatology, 31
J. Pawlotsky, L. Tsakiris, F. Roudot-thoraval, C. Pellet, L. Stuyver, J. Duval, D. Dhumeaux (1995)
Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C.The Journal of infectious diseases, 171 6
T. Poynard, P. Marcellin, Samuel Lee, C. Niederau, International Group (1998)
Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusThe Lancet, 352
(1994)
PreÂvalence des marqueurs de l'heÂpatite C, B et D et aspects histopathologiques dans un groupe de toxicomanes intraveineux
Xavier Forns, Jens Bukh (1999)
The molecular biology of hepatitis C virus. Genotypes and quasispecies.Clinics in liver disease, 3 4
Fukizumi Fukizumi, Sata Sata, Suzuki Suzuki, Nakano Nakano, Tanikawa Tanikawa (1997)
Hepatitis C virus seroconversion in a hyperendemic area of HCV in JapanScand J Infect Dis, 29
Hepatitis C virus (HCV) genotypes are distributed differently depending on geography and route of infection. We characterized the distribution of genotypes in a large cohort of patients with chronic hepatitis C in the South‐east of France and evaluated the relative prevalence according to time of acquisition. One thousand, one hundred‐and‐eighty‐three patients who were anti‐HCV‐positive were studied. HCV genotype distribution has changed significantly from the 1960s to 2000. The prevalence of genotype 1b decreased from 47% before 1978 to 18.8% in the 1990s while the prevalence of genotype 1a and 3a increased during the same period from 18% and 15.3% to 28.8% and 26.3%, respectively. The logistic regression model showed that genotype 1a was significantly more common in patients infected through intravenous drug injection odds ratio ((OR): 2.08, P < 0.01) and after 1990 (OR: 1.98, P < 0.05). Genotype 1b was significantly less frequent in patients infected through intravenous drug injection (OR: 0.17, P < 0.001) and has decreased since 1978 (OR: 0.27, P < 0.001). Genotype 3a was independently associated with intravenous drug injection (OR: 6.1, P < 0.001) and tattooing (OR: 8.01, P < 0.001) and was more frequent in the 1979–90 period (OR: 2.05 and 1.74, P < 0.001 and P < 0.05). Our results show a modification of HCV genotypes distribution over the last four decades due to an increase of intravenous drug use (IVDU) contamination and an evolution of HCV genotypes distribution only in IVDU population characterized by a decrease of genotype 1b, an increase of genotype 3a from 1970 to 1990 and a higher increase of genotype 1a which is currently the predominant genotype in our population.
Journal of Viral Hepatitis – Wiley
Published: Jan 1, 2002
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.